Bristol-myers Squibb Compnay

Viiv Healthcare UK (no.5) Limited

Viiv Healthcare UK (no. 4) Limited

Bristol Meyers Squibb Company

Other

Viiv Healthcare UK Limited

Bristol-myers Squibb Holdings Ireland

Sirard, Pierre

Levesque, Kathia

Thoraval, Dominique

Nicholas A Meanwell

John F Kadow

Tao Wang

Zhongxing Zhang

Makonen Belema

Alicia Regueiro-Ren

Jeffrey Lee Romine

David R Langley

Van N Nguyen

Omar D Lopez

Lawrence G Hamann

Edward H Ruediger

Denis R St Laurent

Daniel H Deon

Jason T Goodrich

Lawrence B Snyder

Andrew Charles Good

Zhiwei Yin

Carol Bachand

Sing-Yuen Sit

Piyasena Hewawasam

Alain Martel

Jie Chen

Ny Sin

John A Bender

Gan Wang

Paul Michael Scola

Kap-Sun Yeung

Yan Chen

Yasutsugu Ueda

Qiufen May Xue

Owen Brendan Wallace

John E Starrett, Jr

Robert G Gentles

Michael A Poss

Li-Qiang Sun

Annapurna Pendri

Yi Zhang

B Narasimhulu Naidu

Clint A James

Jacob Swidorski

Fukang Yang

Rico Lavoie

Zheng Liu

Brian Lee Venables

Alan Xiangdong Wang

Rita Civiello

Kuo-Long Yu

Richard A Hartz

Timothy P Connolly

Zhong Yang

Xiangdong Alan Wang

Scott W Martin

Valentin K Gribkoff

David J Carini

Nachimuthu Soundararajan

Chung-Pin H Chen

Shawn K Pack

Claudio Mapelli

Kenneth M Boy

Kevin W Gillman

Ying Han

Bradley C Pearce

Yunhui Zhang

Eric P Gillis

Min Ding

Eric Mull

Michael A Walker

John D Matiskella

Ramkumar Rajamani

Yong Tu

Kandhasamy Sarkunam

Brett R Beno

Michael H Serrano-Wu

Thomas W Hudyma

Manoj Patel

Qian Zhao

Xiaofan Zheng

Muzammil M Mansuri

Kevin M Peese

Stanley V D'Andrea

Yuping Qiu

David R Tortolani

Michael S Bowsher

Mark George Saulnier

Jeffrey Allen Campbell

Katharine A Grant-Young

David Bertil Frennesson

Samuel Gerritz

Michael Matthew Miller

Margaret E Sorenson

George L Trainor

Francis Beaulieu

Manoranjan Panda

Haiquan Fang

Srinivasan Thangathirupathy

Thomas Stephen Coulter

Min Gao

The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

Immunomodulators

This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein:  Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein:

Salts of prodrugs of piperazine and substituted piperidine antiviral agents

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: These compounds are useful for the treatment of HIV and AIDS.

C-3 and C-17 modified triterpenoids as HIV-1 inhibitors

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: with X selected from Ccycloalkyl, Ccycloalkenyl, Cspirocycloalkyl, Cspirocycloalkenyl, Coxacycloalkyl, Cdioxacycloalkyl, Coxacycloalkenyl, Cdioxacycloalkenyl, Ccyclodialkenyl, Coxacyclodialkenyl, Coxaspirocycloalkyl and Coxaspirocycloalkenyl ring, such that X is substituted with A, wherein A is &#x2014;Calkyl-halo. These compounds are useful for the treatment of HIV and AIDS.

Triterpenoids with HIV maturation inhibitory activity

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Hepatitis C virus inhibitors

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, azadecaline derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: These compounds are useful for the treatment of HIV and AIDS.

Azadecalin derivatives as inhibitors of human immunodeficiency virus replication

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I:  These compounds are useful for the treatment of HIV and AIDS.

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: 

Inhibitors of human immunodeficiency virus replication

The present disclosure provides novel macrocyclic compounds which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

C17-aryl substituted betulinic acid analogs

Compounds of Formula I with activity against HIV, including pharmaceutical compositions and methods for using these compounds in treating human immunodeficiency virus (HIV) infection, are set forth: 

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I and II: These compounds are useful for the treatment of HIV and AIDS.

Oxolupene derivatives

Growing community of inventors

East Hampton, CT, United States of America

Nicholas A Meanwell